Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Feasibility Study of Remote Problem Management Plus for Adults Affected by COVID-19 (PM+)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04617262
Recruitment Status : Recruiting
First Posted : November 5, 2020
Last Update Posted : July 14, 2021
Sponsor:
Collaborator:
George Washington University
Information provided by (Responsible Party):
The New School

Brief Summary:
This is a pilot feasibility study of remotely delivered Problem Management Plus, a low-intensity psychological intervention, delivered in five sessions to adults affected by crisis. The current study will evaluate the feasibility and acceptability of the intervention when delivered remotely via Zoom to community members in New York City impacted by the COVID-19 pandemic. The investigator's goal is to use qualitative and quantitative approaches to inform procedures for a subsequent cluster randomized control trial of Problem Management Plus versus enhanced usual care. A mixed-methods design will be used to evaluate the feasibility, acceptability, perceived utility, and impact of the remotely delivered PM+ intervention, to determine recruitment and retention rates, to assess ethics and safety of trial procedures. Additionally, the study will evaluate the acceptability, feasibility and fidelity of the remote training and supervision of helpers trained to deliver the intervention.

Condition or disease Intervention/treatment Phase
Depression Anxiety Disorders Psychological Distress Behavioral: Remote Problem Management Plus Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Feasibility Study of Remote Problem Management Plus to Improve Well-being and Functioning of Adults Affected by COVID-
Actual Study Start Date : January 27, 2021
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Remote Problem Management Plus
Five individual sessions of low-intensity psychological intervention
Behavioral: Remote Problem Management Plus
Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support




Primary Outcome Measures :
  1. Psychological Outcomes Profile; Unabbreviated scale title "Psychological Outcomes Profile" [ Time Frame: 1 week post-intervention ]
    4-item measure of personalized distress and client-generated problems, function and wellbeing; minimum value = 0, maximum value = 20; higher scores mean greater distress

  2. Patient Health Questionnaire; Unabbreviated scale title "Patient Health Questionnaire" [ Time Frame: 1 week post-intervention ]
    9-item measure of depression symptoms; minimum value = 0, maximum value = 27; higher scores mean more severe depression symptoms

  3. Generalized Anxiety Disorder Scale; Unabbreviated scale title "Generalized Anxiety Disorder 7-item Scale" [ Time Frame: 1 week post-intervention ]
    7-item measure of anxiety symptoms; minimum value = 0 and maximum value = 21; higher scores mean more severe anxiety symptoms


Secondary Outcome Measures :
  1. World Health Organization Disability Assessment Scale 2.0; Unabbreviated scale title "World Health Organization Disability Assessment Scale 2.0" [ Time Frame: 1 week post-intervention ]
    12-item measure of ability to engage in daily activities and functioning; minimum value = 0, maximum value = 48; higher scores mean worse disability outcomes

  2. World Health Organization Quality of Life Questionnaire-BREF; Unabbreviated scale title "World Health Organization Quality of Life Questionnaire-BREF" [ Time Frame: 1 week post-intervention ]
    26-item quality of life assessment of physical health, psychological health, social, relationships and environment; minimum value = 26 and maximum value = 130; higher scores mean better quality of life

  3. EuroQoL 5-dimension 5-level; Unabbreviated scale title "EuroQoL 5-dimension 5-level" [ Time Frame: 1 week post-intervention ]
    5-item assessment of dimensions of health status: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; minimum= 5, maximum = 25; higher score mean worse health outcomes

  4. Pittsburgh Sleep Quality Index; Unabbreviated scale title "Pittsburgh Sleep Quality Index" [ Time Frame: 1 week post-intervention ]
    19-item measure of sleep quality and disturbance; 19 items combined to form 7 "component" scores, each of which has a range of 0-3 points, 7 component scores are added to yield one global global score; minimum value = 0 and maximum value = 21; higher score means greater difficulty sleeping

  5. Somatic Symptom Scale-8; Unabbreviated scale title "Somatic Symptom Scale-8" [ Time Frame: 1 week post-intervention ]
    8-item assessment of the presence and severity of common somatic symptoms; minimum value = 0, maximum value = 32; higher score means more severe somatic symptoms



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • English-speaking
  • Help- or treatment-seeking
  • Access to a device for conducting sessions via Zoom (e.g., smartphone, tablet, laptop or personal computer)

Exclusion Criteria:

  • Acute medical conditions or severe cognitive impairment (e.g., severe intellectual disability or dementia)
  • Imminent suicide risk or expressed acute needs/protection risks (e.g., IPV risk)
  • Presence of severe mental disorder (e.g., psychotic disorders)
  • Hazardous substance use, substance dependency or substance use disorder (assessed using the DAST-10 and AUDIT-C)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04617262


Contacts
Layout table for location contacts
Contact: Kendall Pfeffer, MEd, MA 212-229-5727 pfefk996@newschool.edu
Contact: Adam Brown, PhD 212-229-5727 brownad@newschool.edu

Locations
Layout table for location information
United States, New York
The New School Recruiting
New York, New York, United States, 10011
Contact: Kendall Pfeffer, MEd, MA    212-229-5727    pfefk996@newschool.edu   
Contact: Adam Brown, PhD    212-229-5727    brownad@newschool.edu   
Sponsors and Collaborators
The New School
George Washington University
Investigators
Layout table for investigator information
Principal Investigator: Adam Brown, PhD The New School
Study Director: Brandon Kohrt, MD, PhD George Washington University
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: The New School
ClinicalTrials.gov Identifier: NCT04617262    
Other Study ID Numbers: 2020-91-PM+
First Posted: November 5, 2020    Key Record Dates
Last Update Posted: July 14, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual patient data will be available through NIMH Data Archive after publication of primary results.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Analytic Code
Time Frame: Materials will be shared after publication of primary results.
Access Criteria: Contact investigators.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anxiety Disorders
Mental Disorders